NCT03492112 - A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions

Hepatitis C

Interventions

DEVICE

HCV RNA Point of Care

Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.

DRUG

Sofosbuvir/velpatasvir

Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.

DRUG

Glecaprevir/pibrentasvir

Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.

Trial Locations (1)

2010

NUAA NSP, Sydney